WHO widens device prequalification, but the first review windows are staggered
The World Health Organization has widened the range of medical devices it can assess for prequalification, including contraceptives and software that reads chest X-rays for tuberculosis screening. The September 25 announcement describes a larger quality-assurance route for international procurement. It does not mean every newly eligible device has already passed assessment or reached a clinic.
The timetable is more precise than the headline. Under WHO's eligibility schedule, updated September 25, contraceptive products previously submitted to the United Nations Population Fund (UNFPA), together with computer-aided detection software for TB and male circumcision devices, become eligible for WHO assessment on October 1, 2026. Contraceptive devices that were not previously submitted to and accepted by UNFPA become eligible on April 1, 2027. Changes to contraceptive devices already on UNFPA's list can be submitted to WHO from October 1.
That staged transfer matters to manufacturers and buyers. UNFPA has long published joint WHO/UNFPA guidance for male and female condoms and intrauterine devices. The first wave gives products already in that process a path into WHO's broader framework. A new applicant cannot treat the expansion announcement as an immediate invitation to submit a previously unreviewed contraceptive product. WHO also says eligibility does not guarantee acceptance: it reviews a pre-submission form before confirming that an application can proceed.
A screening tool, not a diagnosis
The software category is similarly specific. WHO lists computer-aided detection tools intended to interpret digital chest X-rays for TB screening and triage. Its TB policy statement concerns screening people aged 15 and older and describes further evaluation after a screen. The new prequalification scope is a product-quality assessment route; it does not turn an algorithm's screening score into a confirmed TB diagnosis.
There is also a practical submission detail. WHO's ePQS portal instructions currently say contraceptive-device applications cannot be made through that portal and direct prospective applicants to contact the prequalification unit. That instruction is consistent with a phased opening, and applicants should follow WHO's current product-specific process rather than assume the general portal accepts every device.
The near-term change is in the review pipeline: more kinds of devices can enter a common WHO assessment framework on stated dates. Whether that leads to more prequalified products, affordable procurement, or improved access is a later outcome to measure, not a result established by this announcement.